Acumen Pharma (ABOS): Projected Price to Earnings
The high probability of Alzheimer's therapy failure and R&D expenditures create financial instability, which is reflected in the expected P/E metric for Acumen Pharmaceuticals (ABOS), where the figure remains around 0.00. However, the success of Phase 2 and interest from Big Pharma in M&A deals mitigate these risks. Strong confidence among neurologists in the scientific brand of Acumen Pharmaceuticals confirms the asset's long-term potential.
Acumen Pharmaceuticals, Inc (ABOS) - metric breakdowns and financial figures
- stock quotes and analyst forecast:
- stock exchange capitalization data:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity Acumen Pharmaceuticals|ABOS - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Acumen Pharmaceuticals|ABOS - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Acumen Pharmaceuticals Inc.|ABOS - Long-Term Liabilities|Company Short-Term Debts Acumen Pharmaceuticals|Quick Ratio acumenpharm.com
- company profitability and valuation multiples indicators:
ABOS - Net Profit|Expected Profit Acumen Pharmaceuticals|ABOS - Company Value to Net Income|Future Price to Earnings Acumen Pharma|ABOS - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Acumen Pharmaceuticals Inc.|ABOS - Operating profit EBITDA|Net earnings per share (EPS TTM) Acumen Pharmaceuticals|ABOS - Net earnings per share for the last 12 months|Quarterly EPS earnings growth acumenpharm.com|ABOS - Earnings per share growth rate in current year|Expected earnings per share growth for next year Acumen Pharmaceuticals
Fundamental valuation:ABOS Acumen Pharmaceuticals, Inc.
Forward P/E reflects the ratio of current market capitalization to expected net income, allowing investors to assess the value of future earnings and the asset's resilience to macroeconomic shocks. By analyzing changes in the future P/E level of Acumen Pharmaceuticals (ABOS), one can see how the strategic R&D alliance for the development of an Alzheimer's drug reduces financial risks and shapes the fair cost of capital for Acumen Pharmaceuticals.
Competitor analysis for Acumen Pharmaceuticals
Forward P/E Multiple BIIB|Projected Price to Earnings Neurocrine NBIX|Regencell - Projected Price to Earnings|Forward P/E Multiple Axsome Corp AXSM|ACAD - Future Price to Earnings|xenon-pharma.com (XENE) - Projected Price to Earnings|VKTX: Forward P/E Multiple|Projected Price to Earnings Ratio Supernus Pharmaceuticals, Inc. (SUPN)|Future Price to Earnings Catalyst Pharmaceuticals Inc|Price to Future Earnings Ratio DNLI (Denali Corp)|Projected Price to Earnings HRMY (Harmony Biosciences)|BHVN (biohavenpharma.com) - Future Price to Earnings Multiple|Future Price to Earnings Amylyx Pharmaceuticals, Inc. AMLX|TRVI (Trevi Therapeutics Inc) - Price to Expected Earnings Ratio|Praxis Medicines - Forward P/E Multiple|Future Price to Earnings Multiple AVXL (Anavex Life Sciences Corp)|CBLL: Forward P/E Multiple|Prothena (PRTA) - Forward P/E Multiple|Future Price to Earnings Alector Inc.|ANNX: Future Price to Earnings Multiple|Future Price to Earnings Omeros Corporation (OMER)|Projected Price to Earnings Neurogene Therapeutics NGNE|Forward P/E Multiple ACIU (AC Immune)|Forward P/E Multiple voyagertherapeutics.com VYGR|Neumora Therapeutics, Inc. - Forward P/E Multiple|Scilex Holding (SCLX) - Projected Price to Earnings|TVGN: Forward P/E Multiple|Projected Price to Earnings Ratio Alpha Cognition Inc. (ACOG)|Projected Price to Earnings CGTX|Forward P/E Multiple inhibikase.com|Projected Price to Earnings SAVA (Cassava Sciences)|Market Cap to Future Earnings Ratio ASRT|Forward P/E Multiple COYA (Coya Therapeutics)|Market Cap to Projected Earnings VistaGen Therapeutics, Inc. (VTGN)|Ovid Rx - Forward P/E Multiple|cervomed.com (CRVO) - Projected Price to Earnings|ATHE: Forward P/E Multiple|Clene (CLNN) - Forward P/E Multiple|Future Price to Earnings PepGen Inc|Future Price to Earnings JUNS|Future Price to Earnings Relmada Therapeutics (RLMD)|Market Cap to Projected Earnings annovisbio.com|Forward P/E Multiple GRCE (Grace Therapeutics)|Forward P/E Multiple Firefly Neuroscience, Inc. AIFF|ANEW Medical, Inc. - Forward P/E Multiple|NRSN: Future Price to Earnings|Reviva Pharmaceuticals (RVPH) - Future Price to Earnings|Projected Price to Earnings Ratio MetaVia (MTVA)|Future Price to Earnings NeurAxis|Helius Medical Technologies Inc. (HSDT) - Market Cap to Projected Earnings|Future Price to Earnings Passage Bio, Inc. (PASG)|bionomics.com.au - Price to Future Earnings Ratio|Forward P/E Multiple NERV (Minerva Neurosciences)|athira.com (ATHA) - Projected Price to Earnings Ratio|ADXN: Projected Price to Earnings|ALZN - Forward P/E Multiple|cyclerion.com (CYCN) - Future Price to Earnings|Protagenic Therapeutics, Inc. - Future Price to Earnings Multiple|Future Price to Earnings Pasithea Therapeutics Corp|Projected Price to Earnings Ratio Cortigent Medical CRGT|Forward P/E Multiple ATXI|Forward P/E Multiple Brainstorm Cell Therapeutics Inc. (BCLI)|Forward P/E Multiple CARA (Cara Therapeutics, Inc)|CHRO - Projected Price to Earnings|ELYM: Projected Price to Earnings|ITCI - Forward P/E Multiple|Longboard Pharmaceuticals, Inc. (LBPH) - Future Price to Earnings|Projected Price to Earnings Marinus Pharmaceuticals Inc|NKGN (NKGen) - Forward P/E Multiple|Projected Price to Earnings Ratio NeuroBo Pharma NRBO|Future Price to Earnings Sage Therapeutics, Inc. (SAGE)|synaptogen.com - Price to Future Earnings Ratio|Trevena - Projected Price to Earnings|Future Price to Earnings Multiple VIGL|WENA - Future Price to Earnings|Price to Expected Earnings Ratio CERE
